Sheri A. Berenbaum, Ph.D.
Penn State University
University Park, Pa.
Sheri A. Berenbaum is professor of psychology and pediatrics and a member of the Neuroscience Institute at The Pennsylvania State University. She received her Ph.D. from the University of California, Berkeley, and completed postdoctoral training at the University of Minnesota. Her research focuses on genetic and neuroendocrine influences on the development of human cognition and social behavior. She is particularly interested in the effects of prenatal sex hormones on the development of sex-typed behaviors and the application of research to optimal treatment of children with disorders of sex development. Her research has been consistently supported by the National Institutes of Health, and she has published extensively. Dr. Berenbaum is currently associate editor of Hormones and Behavior, a present or past member of several journal editorial boards, and a regular reviewer of grant applications for federal funding agencies in the US and other countries. She is a fellow of the American Psychological Association and the Association for Psychological Science and has provided service to several scientific organizations. She has participated in consensus conferences concerned with treatment of children with endocrine disorders and is an advisor to the CARES Foundation.
Madeline Deutsch, M.D.
University of California, San Francisco
San Francisco, Calif.
Dr. Maddie Deutsch, M.D., is the clinical lead at the UCSF Center of Excellence for Transgender Health. She is an assistant clinical professor in the department of family and community medicine and provides transgender-oriented primary care at the UCSF-Mt. Zion Women's Health Primary Care clinic. Dr. Deutsch spends two days per week in Los Angeles as the director of the Transgender Health Program at the L.A. Gay and Lesbian Center, a federally-qualified health center and Ryan White grantee; in Los Angeles, she has a current panel of more than 800 transgender patients for whom she provides primary and hormone care.
Dr. Deutsch has conducted research on the effects of hormone therapy on lipids and other cardiovascular health indicators, as well as cervical cancer screening in transgender men and practices in gender identity data collection and electronic medical record implementation. She is part of an evaluation and technical assistance team funded by the Health Resource Services Administration as part of a nine-site demonstration project examining linkage into and retention in care of HIV-positive transgender women of color. She earned her medical degree from the Chicago Medical School in 2001, completed her residency at Harbor-UCLA Medical Center in 2004 and is currently enrolled in a master of public health program at the UCLA-Fielding School of Public Health.
William G. Reiner, M.D.
University of Oklahoma College of Medicine
Oklahoma City, Okla.
Dr. Reiner's research interests span the areas of child development in children and adolescents with classical bladder exstrophy, cloacal exstrophy, hypospadias, absence of female or male genitals and other major pediatric genital birth defects. Developmental areas of interest in these children include the key aspects of psychosocial development, but also health-related quality of life outcomes. These children also may have errors of gonad development or endocrinological errors of hormone production or effects. Thus, psychosocial child development necessarily must emphasize psychosexual developmental research in these children and adolescents. Specific topics of research interest include: gender identity (the sense of maleness or the sense of femaleness as the child develops); the impact of genital function and appearance on the child's development as well as on their parents; urinary incontinence and function and the impact on the child's development and parents; anxiety about peer and social relations, sexual development, and romantic relationships; how surgeries on the genitals and urinary tract affects the child's development and parent-effectiveness.
As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.